Aptose Biosciences Inc.

Recent News View All News

Aptose Treats First Patient with Continuous Dosing of New “G3” Formulation of Luxeptinib

Nov 14, 2022 7:30am EST

Aptose Clinical Data to be Presented at the 2022 ASH Annual Meeting

Nov 3, 2022 9:10am EDT

Upcoming Events View IR Calendar

64th American Society of Hematology (ASH) Annual Meeting and Exposition

Dec 11, 2022 • 6:00 pm - 8:00 pm EST

View IR Calendar

Email Alerts

Sign up for email alerts for Press Releases & SEC Filings